Some of the best investment opportunities are not always the most talked about.

While large-cap names tend to dominate headlines, there are a number of ASX shares quietly building strong growth platforms behind the scenes. For investors willing to look beyond the obvious, these companies can offer compelling long-term potential.

Here are two under-the-radar ASX shares that could be worth considering.

Breville Group Ltd (ASX: BRG)

The first ASX share that could have significant long-term potential is Breville.

At first glance, Breville might look like a traditional appliance business. But underneath the surface, it is evolving into a global premium consumer brand with multiple growth levers.

The company continues to expand internationally, with newer markets such as China, Korea, the Middle East, and Mexico delivering very strong growth. In fact, these newer regions collectively grew more than 50% during the first half, highlighting the early-stage opportunity still ahead.

At the same time, Breville is benefiting from strong demand in its coffee category, which continues to drive growth globally. Its focus on premium products and innovation allows it to maintain pricing power and brand strength.

Another interesting angle is its investment in artificial intelligence. Management is rolling out AI across the entire business, not just as a small initiative but as a company-wide transformation.

Combined with ongoing product development and geographic expansion, this suggests Breville has more to it than a typical consumer discretionary company.

SiteMinder Ltd (ASX: SDR)

Another under-the-radar ASX share with plenty of potential is SiteMinder.

SiteMinder operates a global hotel distribution and revenue platform, sitting at the centre of how accommodation providers manage bookings, pricing, and distribution.

What makes it particularly interesting is its combination of strong growth and improving profitability. The company recently delivered revenue growth of over 25% alongside a significant improvement in earnings, with EBITDA more than doubling.

Its Smart Platform strategy is a key driver here. By expanding its product offering and increasing adoption among customers, SiteMinder is growing both its customer base and the amount it earns per customer.

This is reflected in its rising annual recurring revenue and improving unit economics, which point to a scalable business model with operating leverage.

There is also a strong structural tailwind from the increasing complexity of hotel distribution and pricing, particularly as artificial intelligence becomes more widely adopted across the travel industry. SiteMinder’s platform plays a critical role in executing transactions and managing this complexity, positioning it well for long-term growth.

The post 2 under-the-radar ASX shares with bags of potential appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: ANZ, Breville, and Macquarie shares
• Forget Easter eggs, these ASX shares could be your best buys this month
• 3 of the best ASX 200 shares to buy this month with $6,000
• How to invest during an ASX share bear market when you’re worried about prices falling more
• Here are the top 10 ASX 200 shares today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended SiteMinder. The Motley Fool Australia has positions in and has recommended SiteMinder. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

There are few businesses that receive substantial analyst positivity on the ASX. But when plenty of analysts rate an ASX share as a buy, investors may want to do some further looking.

The three S&P/ASX 200 Index (ASX: XJO) shares I’m about to note are among the leaders in the world at what they do, and analysts think they have the potential to deliver large capital gains in the long term.

Let’s have a look at what they do and how excited analysts are.

Aristocrat Leisure Ltd (ASX: ALL)

Aristocrat is a major player in the global poker machine and casino management system space. It also has a sizeable mobile game segment.

According to CMC Invest, there have been 9 analyst ratings on the business over the last 3 months, all of which were buy ratings.

The average price target – where analysts think the business will be trading in a year from now – is $67.06. At the time of writing, that suggests a rise of more than 40%.

The most optimistic price target is $73.71, suggesting a possible rise of more than 50%, while the lowest price target is $62.75, implying a suggested rise of more than 30%.

According to the projection on CMC Invest, the ASX share is valued at around 18x FY26’s estimated earnings.

Orica Ltd (ASX: ORI)

The next ASX share I’ll highlight is Orica, which describes itself as a global leader in mining and infrastructure services, explosives manufacturing, digital solutions, and specialty mining chemicals.

According to CMC Invest, there have been 11 recent ratings on the business – all of them were a buy.

The average price target on CMC Invest of $26.08 suggests a possible rise of around 25% at the time of writing, while the highest estimate of $29.88 implies a rise of well over 40%. However, the lowest price target of $23.95 suggests only a 15% potential rise.

Using the earnings forecast on CMC Invest, the business is valued at 17x FY26’s estimated earnings.

Xero Ltd (ASX: XRO)

Xero is one of the world’s leading cloud accounting and payments businesses.

According to CMC Invest, of the seven recent ratings on the ASX tech share, six were buy.

Impressively, the average price target of those ratings is $157.28, suggesting a possible increase of around 100%. The highest price target is $232.88, suggesting it could rise around 200%. That may be a bit ambitious for 2026.

But, not everyone is so confident – the lowest price target is $82.37. That suggests a rise of less than 10% from where it is today.

Based on broker UBS’ projections, the business is valued at 67x FY26’s estimated earnings.

The post Brokers rate these 3 top ASX shares as buys in April appeared first on The Motley Fool Australia.

More reading

• Forget Easter eggs, these ASX shares could be your best buys this month
• 1 ASX dividend share and 1 ASX growth stock to buy in April
• The best time to buy shares? It might be right now
• Top brokers name 3 ASX shares to buy today
• Why are ASX 200 tech stocks like WiseTech and Life360 going gangbusters on Wednesday?

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Xero. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Even the highest-quality companies are not immune to market selloffs.

In fact, periods of uncertainty often see investors pull back from even the most established names. While that can be uncomfortable in the short term, it can also create opportunities to buy leading businesses at more attractive prices.

Here are three ASX blue chips that have fallen heavily and could be worth a closer look.

Cochlear Ltd (ASX: COH)

The first ASX blue chip that could be too cheap to ignore is Cochlear.

The hearing solutions company recently disappointed the market with a softer-than-expected result, driven in part by a slower rollout of its new Nexa system and margin pressure from product mix.

While this has weighed on sentiment, it does not change Cochlear’s long-term position as a global leader in implantable hearing devices.

Demand for hearing solutions continues to grow due to ageing populations and increased awareness. Cochlear also benefits from a large installed base, which generates recurring revenue through upgrades and servicing.

If the company can execute on its product rollout and return to stronger growth, the current weakness could prove temporary.

CSL Ltd (ASX: CSL)

Another ASX blue chip that may be worth considering is CSL.

The biotech giant’s shares have fallen sharply following a soft result and the unexpected CEO transition, which has created uncertainty around its near-term outlook.

The key issue has been weaker-than-expected performance in its CSL Behring division, particularly in immunoglobulin, alongside slower margin recovery than the market had anticipated.

However, CSL still operates in global healthcare markets with strong demand and high barriers to entry. Its therapies address serious medical conditions, and long-term growth drivers remain intact.

While challenges remain, the company’s track record and market position suggest it has the capability to work through this period and return to more consistent growth.

James Hardie Industries plc (ASX: JHX)

A third ASX blue chip that could be trading at an attractive level is James Hardie Industries.

The building materials company has been under pressure due to concerns about housing market weakness, particularly in the United States.

Slower construction activity can weigh on demand for its fibre cement products, which has led to more cautious sentiment from investors.

However, James Hardie remains a leader in its category, with strong brand recognition and a history of gaining market share over time.

When housing activity eventually recovers, the company could be well placed to benefit. In the meantime, it continues to focus on innovation and expanding its product offering.

For investors willing to look beyond the near-term uncertainty, this could make it an interesting option at current levels.

The post Are these ASX blue chips now too cheap to ignore? appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Cochlear, South32, and Westpac shares
• Are ‘50% off’ CSL shares a once-in-a-decade opportunity?
• 3 ASX shares to buy before the next market rally
• 3 ASX shares down 25% (or more) to buy right now
• 3 ASX 200 shares down at least 30% to buy now

Motley Fool contributor James Mickleboro has positions in CSL and Cochlear. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Cochlear. The Motley Fool Australia has recommended CSL and Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The team at Morgans has been busy running the rule over a number of popular ASX 200 shares recently.

But does the broker think they are buys, holds, or sells? Let’s see what it is saying about them:

Cochlear Ltd (ASX: COH)

This hearing solutions company delivered a result that was below expectations during the first half of FY 2026.

And while the broker notes that demand for the new Nucleus Nexa system is increasing, it isn’t enough for a buy rating at this point. It has put a hold rating and $214.93 price target on its shares. However, this is comfortably ahead of the current Cochlear share price of $172.36. It said:

The 1H26 result was softer than expected, with revenue, margins and profit negatively impacted mainly on longer than anticipated contracting for the newly launched Nucleus Nexa system (Nexa). Soft Cochlear Implants (CI) growth mis-matched sales, reflecting unfavourable emerging market mix and delayed developed market momentum, while Services was flat and Acoustics surprised to downside on increased competitive pressures.

While Nexa adoption accelerated late in the half and management maintained FY26 guidance, but now is targeting the lower end of the range, it increases reliance on a strong 2H recovery which appears optimistic, especially in light of flat GM and FX headwinds. We adjust our FY26-28 estimates and lower our target price to A$214.93. We maintain a cautious stance, but move to HOLD on share weakness.

South32 Ltd (ASX: S32)

Unlike Cochlear, this mining giant outperformed expectations during the first half.

While Morgans was impressed with its result, due to its current valuation, it has lowered its rating to accumulate with a $5.00 price target. This compares to the latest South32 share price of $4.42. It said:

Bumper 1H26 EBITDA comfortably ahead of consensus and close to our estimate, riding consistent production and higher base and precious metals. 15% interim dividend beat and upsized capital management of an extra US$100m. Not all positive, Hermosa budget increase flagged for H2 a ST risk to monitor. Guidance unchanged, besides Brazil Aluminium output and capex timing tweaks.

We lower our rating to ACCUMULATE (from BUY) with an unchanged A$5.00 TP, recommending patience when adding following the recent share price surge.

Westpac Banking Corp (ASX: WBC)

Finally, Morgans has been looking at Westpac shares following its first-quarter update.

Although the broker was pleased with the update, it has only been enough to upgrade its shares to a trim rating (between sell and hold) with a $35.12 price target. This compares to the latest Westpac share price of $39.85. It said:

A largely stable 1Q26 result compared to the 2H25 quarterly average (normalised for 2H25’s restructuring charge), which is better than 1H26 expectations. We are assuming a more bullish loan growth and impairments outlook than previously (and slightly more conservative costs).

There is no change to FY26F EPS but there are 5-8% upgrades to FY27-28F. Target price lifts to $35.12/sh. We upgrade to TRIM given the improved, but still negative, potential TSR.

The post Buy, hold, sell: Cochlear, South32, and Westpac shares appeared first on The Motley Fool Australia.

More reading

• 3 ASX shares down 25% (or more) to buy right now
• 3 ASX 200 shares down at least 30% to buy now
• What happened with ASX 200 bank stocks like CBA and Westpac in March?
• The best time to buy shares? It might be right now
• 3 ASX 200 healthcare shares at multi-year lows

Motley Fool contributor James Mickleboro has positions in Cochlear. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

At the start of each week, I like to look at ASIC’s short position report to find out which shares are being targeted by short sellers.

This is because I believe it is well worth keeping a close eye on short interest levels as high levels can sometimes be a sign that something isn’t quite right with a company.

With that in mind, here are the 10 most shorted shares on the ASX this week according to ASIC:

• Domino’s Pizza Enterprises Ltd (ASX: DMP) continues its run as the most shorted ASX share after its short interest rose slightly to 15.3%. It seems that short sellers are betting against the pizza chain operator’s turnaround strategy.
• Telix Pharmaceuticals Ltd (ASX: TLX) has short interest of 14.3%, which is down slightly since last week. This radiopharmaceuticals company failed to gain FDA approval for a couple of its therapies last year. Short sellers don’t appear confident that 2026 will be any better despite a recent resubmission.
• Polynovo Ltd (ASX: PNV) has short interest of 14.2%, which is flat since last week. This may be due to valuation concerns with the medical device company’s shares trading on high earnings multiples.
• Guzman Y Gomez Ltd (ASX: GYG) has short interest of 14.1%, which is up week on week. This quick service restaurant operator’s shares have fallen heavily over the past 12 months due to their premium valuation and concerns that its US expansion could be a failure. The US was supposed to be its largest growth opportunity.
• Boss Energy Ltd (ASX: BOE) has short interest of 12.1%, which is up again since last week. There are major concerns over this uranium miner’s production outlook beyond 2026.
• Treasury Wine Estates Ltd (ASX: TWE) has seen its short interest fall again to 11.6%. This wine giant is battling consumer spending pressures and distributor disruption. Short sellers appear to believe it will get worse before it gets better.
• Nanosonics Ltd (ASX: NAN) has entered the top ten with short interest of 11.8%. This infection prevention technology company’s performance has underwhelmed in recent times. It seems that short sellers aren’t confident a change is coming.
• Flight Centre Travel Group Ltd (ASX: FLT) has short interest of 11.8%, which is up week on week again. Short sellers have been loading up on the travel agent’s shares since the Middle East conflict. There are concerns it could have a negative impact on travel markets.
• DroneShield Ltd (ASX: DRO) has 11.4% of its shares held short, which is up since last week. Short sellers appear to think this counter drone technology company’s shares are overvalued after surging over the past 12 months.
• Lotus Resources Ltd (ASX: LOT) has short interest of 10.2%. This uranium producer is one of a number of stocks in the industry being targeted by short sellers, with several sitting just outside the top ten.

The post These are the 10 most shorted ASX shares appeared first on The Motley Fool Australia.

More reading

• Top brokers name 3 ASX shares to buy next week
• 3 ASX 200 shares down at least 30% to buy now
• $5,000 invested in Droneshield shares 4 months ago is already worth…
• Treasury Wine shares hit 10-year lows last week. So why are buyers stepping in now?
• 3 ASX 200 healthcare shares to buy amid sector rout

Motley Fool contributor James Mickleboro has positions in Domino’s Pizza Enterprises and Treasury Wine Estates. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Domino’s Pizza Enterprises, DroneShield, PolyNovo, Telix Pharmaceuticals, and Treasury Wine Estates and is short shares of DroneShield. The Motley Fool Australia has positions in and has recommended Treasury Wine Estates. The Motley Fool Australia has recommended Domino’s Pizza Enterprises, Flight Centre Travel Group, PolyNovo, and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Do you have room for some new additions to your portfolio?

If you do, let’s see what Morgans is saying about the ASX shares listed below and whether you should be considering a position in them this month.

Here’s what the broker is saying:

ANZ Group Holdings Ltd (ASX: ANZ)

Morgans was relatively pleased with this banking giant’s performance during the first quarter.

While the bank is making strong progress with its cost reductions, the broker highlights that its guidance for the full year remains the same.

As a result, it hasn’t seen anything to make it more positive and has put a sell rating and $32.65 price target on ANZ’s shares. It said:

On face of it, the 1Q26 trading update suggested ANZ was tracking ahead of 1H26 growth expectations. However, the beat was driven mostly by the speed of cost-out and will unlikely affect consensus expectations as ANZ retained its FY26 cost guidance of c.$11.5bn. We make minor adjustments to FY26-28F EPS, reflecting 1Q26 Markets revenue strength, impairment charges lower than expected (but off an already low base), and higher shares on issue (DRP uptake was higher than assumed). 12-month target price $32.65 (+8 cps).

We estimate ANZ is trading on 1.8x P:TBV, 16x PER, and 4.1% cash yield (partly franked), all stretched against historical trading ranges. Given the recent share price strength, we downgrade our rating from TRIM to SELL.

Breville Group Ltd (ASX: BRG)

Morgans is far more positive on this appliance manufacturer.

After a better than expected half-year result, the broker has put a buy rating and $40.65 price target on its shares. This implies potential upside of approximately 50% from its current share price. It said:

1H26 was better-than-feared, with double-digit sales growth (+10%) largely offset by tariff costs (~130bp GM impact) to deliver a flat NPAT outcome (+1% on pcp). Crucially, FY26 EBIT growth guidance provides much-needed earnings visibility, alleviating some concerns for an extended transition year and improving our confidence for a resumption of sustainable EPS growth from FY27+.

We continue to be impressed by BRG’s strong operational execution, green shoots in Food Prep, and powerful medium-term tailwinds (geographic expansion, espresso tailwinds, NPD, Best Buy developments). Buy maintained.

Macquarie Group Ltd (ASX: MQG)

Finally, Morgans is a fan of this investment bank and was pleased with its performance during the third quarter.

However, due to its current valuation, it only has a hold rating and $223.00 price target on its shares. It commented:

MQG has hosted its annual operational briefing, together with releasing its 3Q26 update.  On the 3Q26 update, we saw this as a solid performance overall, benefitting from market-facing businesses (CGM and Macquarie Capital) seeing results “substantially up” on the pcp.

Additionally, there was an underlying upgrade to CGM guidance, albeit this has been offset, to some degree, by an expected higher FY26 tax rate. We lift our MQG FY26F/FY27F EPS by +2%/+4% reflecting the more positive CGM commentary, blunted somewhat by higher expected tax. Our target price rises to ~$223 (from A$214). We maintain our HOLD recommendation.

The post Buy, hold, sell: ANZ, Breville, and Macquarie shares appeared first on The Motley Fool Australia.

More reading

• Forget Easter eggs, these ASX shares could be your best buys this month
• What happened with ASX 200 bank stocks like CBA and Westpac in March?
• 3 of the best ASX 200 shares to buy this month with $6,000
• How to invest during an ASX share bear market when you’re worried about prices falling more
• My best blue-chip ASX 200 buys for April

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Building long-term wealth often comes down to consistency rather than complexity.

Instead of constantly switching between investments, investors could focus on holding a small group of quality exchange traded funds (ETFs) that can grow steadily over time.

With the right mix, it is possible to gain exposure to powerful trends, resilient businesses, and global opportunities all in one portfolio.

With that in mind, here are five ASX ETFs that could be worth buying and holding for the next decade.

VanEck Morningstar Wide Moat ETF (ASX: MOAT)

The first ASX ETF to consider is the VanEck Morningstar Wide Moat ETF.

This ETF focuses on companies with sustainable competitive advantages, often referred to as economic moats. These are businesses that can protect their profits from competitors over long periods.

Rather than simply tracking an index, the fund selects companies it believes are both high quality and attractively priced. This combination can be powerful over time, particularly when markets become more volatile.

Warren Buffett based his whole career on this investment philosophy, and given his success, it is hard to argue against using this strategy.

BetaShares Global Quality Leaders ETF (ASX: QLTY)

Another ASX ETF that could be worth considering is the BetaShares Global Quality Leaders ETF.

This ETF targets companies with strong balance sheets, high returns on equity, and consistent earnings growth. These traits are often associated with businesses that can perform well across different economic environments.

The fund includes a mix of global leaders across sectors, providing diversification while maintaining a focus on quality.

Over a 10-year period, this emphasis on financially strong companies could help smooth returns and support long-term performance. It was recently recommended by analysts at BetaShares.

BetaShares Australian Quality ETF (ASX: AQLT)

A third ASX ETF to consider is the BetaShares Australian Quality ETF.

This fund applies a similar quality-focused approach but within the Australian market. It selects ASX shares with strong profitability, low debt, and stable earnings.

This creates a portfolio that leans towards well-managed businesses rather than simply the largest companies on the ASX.

For investors looking to complement global exposure with high-quality local companies, the BetaShares Australian Quality ETF could be a useful addition to a long-term portfolio. It was also recently recommended by the team at BetaShares.

iShares Global Consumer Staples ETF (ASX: IXI)

Another ASX ETF that could be a strong long-term holding is the iShares Global Consumer Staples ETF.

This ETF provides exposure to global consumer staples companies, which produce everyday goods such as food, beverages, and household items.

These businesses tend to have stable demand regardless of economic conditions, which can provide resilience during periods of uncertainty.

Over time, consistent earnings and dividend growth from these companies can contribute to steady total returns.

BetaShares India Quality ETF (ASX: IIND)

A final ASX ETF to consider is the BetaShares India Quality ETF.

It provides exposure to high-quality stocks in India, which is one of the fastest-growing major economies in the world.

India’s expanding middle class, increasing digital adoption, and structural economic reforms are creating significant opportunities for businesses operating in the region.

By focusing on quality companies within this market, the BetaShares India Quality ETF offers a way to tap into long-term growth while maintaining a disciplined investment approach. It is another fund that was recommended by analysts at BetaShares.

The post 5 ASX ETFs to buy and hold for 10 years appeared first on The Motley Fool Australia.

More reading

• Why these ASX ETFs could be top picks in April
• A simple 3-ETF portfolio I’d use to build long-term wealth
• This simple ASX ETF strategy could quietly build serious wealth
• This ASX ETF is perfect for an uncertain world
• This simple ASX ETF strategy matters more than ever in today’s uncertain market

Motley Fool contributor James Mickleboro has positions in VanEck Morningstar Wide Moat ETF. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended iShares International Equity ETFs – iShares Global Consumer Staples ETF. The Motley Fool Australia has recommended VanEck Morningstar Wide Moat ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Finding ASX shares that can double in value is no easy task.

But history shows that companies with strong competitive advantages, large market opportunities, and scalable business models can deliver outsized returns over time.

In many cases, these businesses are still early in their growth journey, which gives them a long runway to expand.

Here are three ASX shares that could have the potential to double over the next decade, or even sooner if things go their way.

Life360 Inc. (ASX: 360)

The first ASX share that could deliver strong long-term returns is Life360.

It is a family safety and location platform provider that has built a large and highly engaged global user base. Its app provides services such as real-time location sharing, driving reports, and emergency assistance.

What makes Life360 particularly compelling is its monetisation opportunity. While almost 100 million users are already on the platform, only a portion currently pay for premium features. This creates significant upside as the company continues converting free users into paying subscribers.

In addition, Life360 is expanding into new services such as advertising and partnerships, which could further increase revenue per user. With strong growth in users and improving monetisation, the business appears well positioned to scale meaningfully over time.

Netwealth Group Ltd (ASX: NWL)

Another ASX share that could be capable of doubling is Netwealth.

It provides a wealth management platform used by financial advisers and investors. Its platform allows users to manage investments, superannuation, and portfolios in a streamlined and efficient way.

The company has been consistently gaining market share from traditional providers, driven by its modern technology and user-friendly interface.

Importantly, the platform model is highly scalable. As funds under administration grow, revenue increases without a corresponding rise in costs, supporting margin expansion over time.

With structural tailwinds from the shift towards independent advice and digital platforms, Netwealth could continue growing strongly over the next decade.

Pro Medicus Ltd (ASX: PME)

A third ASX share that could deliver outsized returns is Pro Medicus.

It provides imaging software to hospitals and healthcare providers, with its Visage platform offering best-in-class, high-performance diagnostic imaging capabilities.

The company has built a strong position in the United States, where it continues to win large contracts with leading healthcare institutions. These deals are often long-term and high value, providing excellent revenue visibility.

Furthermore, the company’s business model is highly scalable. Once its software is deployed, additional usage comes at minimal incremental cost, which supports very high margins.

With a large addressable market and a proven ability to win new contracts, Pro Medicus appears well placed to continue growing. If it maintains its momentum, its shares could deliver significant returns for investors over the long term, especially after a sharp pullback in 2026.

The post 3 ASX shares that could double over the next decade (or much sooner) appeared first on The Motley Fool Australia.

More reading

• 3 ASX shares down 25% (or more) to buy right now
• Why two experts are urging investors to buy Pro Medicus shares
• 3 ASX 200 healthcare shares to buy amid sector rout
• 3 of the best ASX 200 shares to buy this month with $6,000
• The best time to buy shares? It might be right now

Motley Fool contributor James Mickleboro has positions in Life360 and Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360 and Netwealth Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Life360 and Netwealth Group. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Starting out in the share market can feel intimidating. 

We have all been there. There are thousands of listed companies, constant news flow, and no shortage of opinions about what to buy.

When I think about beginner investors, I try to keep things simple. Focus on businesses that are proven, easy to understand, and have a track record of delivering over time.

Here are three ASX shares that I think fit that description.

Wesfarmers Ltd (ASX: WES)

Wesfarmers is one of the clearest examples of a high-quality Australian business.

It owns well-known consumer brands like Bunnings, Officeworks, and Kmart, which generate consistent earnings and strong cash flow. These are businesses that people interact with regularly, which makes them easier to understand as an investor.

But what I like most is management’s track record. Wesfarmers has shown over many years that it can allocate capital effectively, whether that is investing in existing divisions, expanding into new areas, or exiting businesses that no longer fit.

For a beginner, I think that kind of consistency and discipline is valuable from an ASX share.

ResMed Inc. (ASX: RMD)

ResMed offers something different. This is a global healthcare company focused on sleep and respiratory conditions, particularly sleep apnoea.

The opportunity here is large and long term. Millions of people around the world remain undiagnosed or untreated, and trends like ageing populations and increasing awareness of sleep health continue to support demand.

What stands out to me is how the business combines growth with quality. It is not just expanding. It is doing so with strong margins, solid cash flow, and a growing digital ecosystem that connects patients and providers.

For beginners, I think ResMed introduces exposure to global growth in a relatively understandable way.

Hub24 Ltd (ASX: HUB)

Hub24 brings in a different type of growth again. It operates a platform used by financial advisers to manage client investments. This is part of a broader shift toward digital wealth management.

The key driver here is scale. As more advisers use the platform and more client funds are added, the business can grow revenue while spreading its costs across a larger base.

That creates the potential for strong earnings growth over time.

It is a bit more complex than a retailer or healthcare company, but the core idea is straightforward. It is a platform that becomes more valuable as more money flows through it.

Foolish takeaway

For beginner investors, I think the goal should be to start with quality and keep things manageable.

I think Wesfarmers offers stability and a proven business model, ResMed provides exposure to long-term healthcare growth, and Hub24 adds a platform-driven growth story tied to structural changes in financial services.

Overall, I think they could be suitable starting points for a long-term portfolio.

The post 3 quality ASX shares to buy for a beginner investor appeared first on The Motley Fool Australia.

More reading

• 3 ASX shares to buy before the next market rally
• 3 ASX defensive shares to buy in uncertain markets
• 3 reasons to buy Wesfarmers shares today
• The best time to buy shares? It might be right now
• How are these 5 ASX share giants really tracking in 2026?

Motley Fool contributor Grace Alvino has positions in Hub24 and Wesfarmers. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Hub24, ResMed, and Wesfarmers. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Hub24 and Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

It was another busy week for Australia’s top brokers. This has led to the release of a number of broker notes.

Three broker buy ratings that you might want to know more about are summarised below. Here’s why brokers think these ASX shares are in the buy zone:

DroneShield Ltd (ASX: DRO)

According to a note out of Bell Potter, its analysts have retained their buy rating and $4.80 price target on this counter-drone technology company’s shares. Bell Potter has been looking at the counter-drone industry and highlights that the Middle East conflict is accelerating demand for the technology. The broker notes that lessons learned in Ukraine are being repeated, including the realisation that using up to US$4 million missiles to take down US$35,000 drones is unsustainable. In light of this, Bell Potter expects there to be broad adoption of C-UAS technologies alongside advanced hypersonic defence capabilities to improve on this equation. It feels that this bodes well for DroneShield given its strong position in the market and high-quality product portfolio. The DroneShield share price ended the week at $3.93.

Navigator Global Investments Ltd (ASX: NGI)

A note out of Morgans reveals that its analysts have retained their buy rating on this investment company’s shares with a reduced price target of $2.98. Morgans I had spoken positively about the company’s decision to acquire Georgian. It is a Toronto-based AI-focused growth equity firm. The broker thinks the deal is a strategic fit and will be earnings accretive. In addition, Morgans highlights that a recent selloff of Navigator Global shares appears to be linked to private credit concerns around its key strategic partner Blue Owl. However, Morgans thinks that the company’s fundamentals are largely unchanged, creating a buying opportunity for investors. The Navigator share price was fetching $2.05 at Thursday’s close.

Nufarm Ltd (ASX: NUF)

Another note out of Bell Potter reveals that its analysts have retained their buy rating and $3.60 price target on this agricultural chemicals company’s shares. Bell Potter notes that we are entering the most material selling windows for Nufarm. The good news for Nufarm is that the majority of markets look supportive of reasonable demand levels of crop protection products. In addition, Bell Potter points out that upward movements in active ingredients and omega-3 indicators all look supportive of a reasonable pricing environment. It feels that this leaves Nufarm in a position to deleverage its balance sheet, which could be a positive share price catalyst. The Nufarm share price ended the week at $2.03.

The post Top brokers name 3 ASX shares to buy next week appeared first on The Motley Fool Australia.

More reading

• Brokers name 3 ASX shares to buy right now
• Why these ASX shares are rated as buys in April
• 3 ASX 200 shares down at least 30% to buy now
• $5,000 invested in Droneshield shares 4 months ago is already worth…
• Is this ASX defence stock the next DroneShield?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended DroneShield and is short shares of DroneShield. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.